• Policy
• Negotiations on Strepto, concluded in the early 20% range
• by Lee, Tak-Sun Nov 15, 2022 05:39am

• Opinion
• [Reporter’s View] Advanced new drugs, reimb, and patients
• by Eo, Yun-Ho Nov 15, 2022 05:39am

• Company
• Tecentriq approved as adjuvant treatment for NSCLC
• by Nov 15, 2022 05:38am

• Company
• CR of AML new drug candidates is identified in Phase 1/2
• by Kim, Jin-Gu Nov 15, 2022 05:38am

• Company
• Merck KGaA has appointed Christoph Hamann
• by Nov 15, 2022 05:38am

• Policy
• The vaccine fund will be increased by ₩40 billion
• by Lee, Jeong-Hwan Nov 14, 2022 06:07am

• Company
• Adding AUS as a drug price reference country raise concerns
• by Nho, Byung Chul Nov 14, 2022 06:07am

• Company
• Heart failure drug Entresto makes KRW 10 bil in Q3
• by Kim, Jin-Gu Nov 14, 2022 06:07am

• Company
• The market is recovering for the first time in two years
• by Kim, Jin-Gu Nov 14, 2022 06:07am

• Company
• The popular Daewoong's Nabota
• by Nov 14, 2022 06:06am